You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

27 Items
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Dec 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, according to clinical criteria
May 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Aug 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Drugs Used:
aXitinib (Unfunded),
pembrolizumab (Unfunded)
Jan 2020
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Sep 2016
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Gynecologic, Gestational Trophoblastic Disease     
Intent: Curative
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
New Drug Funding Program
    Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
Nov 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Nov 2019
Cancer Type: Head and Neck     
Intent: Palliative
Nov 2019
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Palliative
Nov 2019